Ontario Lung Cancer Screening Pilot Results – Modern Lung Cancer Screening Performance in a Universal Health Care Setting
Author:
Tammemagi Carl1ORCID, Darling Gail1, Schmidt Heidi1, Walker Meghan2, Langer Deanna1, Leung Yvonne1, Nguyen Kathy1, Miller Beth1, Llovet Diego1ORCID, Evans William1, Buchanan Daniel1ORCID, Espino-Hernandez Gabriela1, Aslam Usman1, Sheppard Amanda1, Lofters Aisha1, McInnis Micheal3, Dobranowski Julian1, Habbous Steven1, Finley Christian1, Luettschwager Marianne1, Cameron Erin1, Bravo Caroline1, Banaszewska Anna1, Creighton-Taylor Katherin1, Fernandes Brenda1, Gao Julia1, Lee Alex1, Lee Van1, Pylypenko Bogdan1, Yu Monica1, Svara Erin1, Kaushal Shivali1, MacNiven Lynda1, McGarry Caitlin1, Mora Lauren Della1, Koen Liz1, Moffatt Jessica1, Rey Michelle1, Yurcan Marta1, Bourne Laurie1, Bromfield Gillian1ORCID, Coulson Melissa1, Truscott Rebecca1, Rabeneck Linda1
Affiliation:
1. Ontario Health (Cancer Care Ontario) 2. University of Toronto - Ontario Health (Cancer Care Ontario) 3. University Health Network
Abstract
Abstract
Globally, lung cancer is the leading cause of cancer death. The U.S. National Lung Screening Trial and Dutch-Belgium NELSON trial demonstrated that low-dose computed tomography lung cancer screening (LCS) of high-risk individuals can reduce lung cancer mortality by ≥20%. LCS has been approved by major guidelines in the U.S. with over 4,000 different sites offering screening. Adoption of LCS outside of the U.S. has been slow. The Ontario LCS Pilot successfully recruited and enrolled 7768 individuals at high risk for lung cancer between June 1, 2017, and May 31, 2019. 4451 Pilot participants were successfully screened, retained, and provided with high quality follow-up including appropriate treatment as needed. The Pilot lung cancer detection rate and proportion of early-stage disease were high at 2.4% and 79.2%, respectively, and serious harms were low. The Ontario LCS Pilot provides insights into how a modern organized lung screening program can be implemented in a large, diverse, populous geographic area within a universal health care system.
Publisher
Research Square Platform LLC
Reference42 articles.
1. Sung H, Ferlay J, Siegel RL, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA: a cancer journal for clinicians 2021; 71(3): 209 – 49. 2. Canadian Cancer Statistics Advisory Committee. Canadian Cancer Statistics: A 2020 special report on lung cancer. Toronto, ON: Canadian Cancer Society, 2020. Available at: cancer.ca/Canadian-Cancer-Statistics-2020-EN. Accessed 22 October 2020. 3. Reduced lung-cancer mortality with low-dose computed tomographic screening;Aberle DR;The New England journal of medicine,2011 4. Preventive Services Task Force. Screening for lung cancer: U.S. Preventive Services Task Force recommendation statement;Moyer VA;Annals of internal medicine,2014 5. Centers for Medicare & Medicaid Services (CMS). Decision Memo for Screening for Lung Cancer with Low Dose Computed Tomography (LDCT) (CAG-00439N). https://www.cms.gov/medicare-coverage-database/details/nca-decision-memo.aspx?NCAId=274&NcaName=Screening+for+Lung+Cancer+with+Low+Dose+Computed+Tomography+(LDCT)&MEDCACId=68&IsPopup=y&bc=AAAAAAAAAgAAAA%3d%3d&. Accessed 31 August 2015., 2015.
|
|